International Mastocytosis and Mast Cell Diseases Awareness Day 2022

October 17, 2022

Since early in our company’s history, we’ve been deeply committed to advancing care for systemic mastocytosis as we aim to address unmet patient needs. This…

Read more

AACR Annual Meeting 2022: Showcasing our Precision Therapy Pipeline

April 8, 2022

At the American Association for Cancer Research (AACR) Annual Meeting 2022, we’re presenting new clinical and preclinical data for multiple programs across our precision therapy…

Read more

Implementing a meaningful and sustainable equity, diversity and inclusion strategy

January 18, 2022 by Jessica Kline, Director of Internal Communications & Corporate Social Responsibility, and Rizwana Seeham, Senior Manager of GMP Quality Assurance & ED&I

Originally published on MassBio.org December 20, 2021 At Blueprint Medicines, we’ve been committed to equity, diversity, and inclusion (ED&I) since our company’s founding in 2011.…

Read more

The right moment for thoughtful transition of leadership at Blueprint Medicines

January 12, 2022 by Jeff Albers and Kate Haviland

Last week, we announced that Jeff Albers, our Chief Executive Officer (CEO), has decided to step down and move into the position of Executive Chairman,…

Read more

Blueprint’s Biomarker Testing Program: KIT D816V Test Available for Eligible U.S. Patients Suspected of Having Systemic Mastocytosis

November 22, 2021 by Ruthvik Malladi, Associate Director, Precision Medicine

Receiving a timely diagnosis is difficult for many patients living with a rare disease. These challenges are particularly significant for systemic mastocytosis (SM), a rare…

Read more

Female Leaders at Blueprint Medicines Bringing
Leadership across the Life Sciences Industry

October 22, 2021 by Jeff Albers

At Blueprint Medicines, we believe diversity is a core strength of our business.  By drawing upon a range of backgrounds, experiences and perspectives, we strengthen…

Read more

Our first decade of innovation in precision medicine

April 21, 2021 by Fouad Namouni

This month marks 10 years since Blueprint Medicines began operations, and it’s a natural time to celebrate the science, patients and people who have made…

Read more

Joining Other Precision Medicine Stakeholders to Develop United Language for Testing

June 11, 2020 by Elissa Quinn, Associate Director, Precision Medicine

With more biomarker-targeted therapies becoming available, patient advocacy groups have increasingly talked about the challenge of confusing terminology for cancer testing. In March 2019, my…

Read more

ASCO 2019: Advancing Cancer Treatment with Precision Therapies

May 31, 2019

At the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, a key focus will be precision therapy – targeting genetic drivers of cancer with…

Read more

Blueprint Medicines Recognizes International FOP Awareness Day

April 23, 2019

Letter from Marion Dorsch, Chief Scientific Officer Today, Blueprint Medicines stands with the patient community and recognizes International Fibrodysplasia Ossificans Progressiva (FOP) Awareness Day. In…

Read more

How Our Research Platform Helped Accelerate the Discovery of BLU-667

April 10, 2019 by Jason Brubaker

Discovering potent and selective kinase drugs is a challenging endeavor. Setting up and completing a screen of a new drug target against a compound library…

Read more

Blueprint Medicines Introduces The Lens

January 2, 2019 by Marion Dorsch, Chief Scientific Officer

Welcome to The Lens, our new thought leadership platform to share our team’s expertise in precision medicine. We are pioneers in this rapidly evolving field,…

Read more